Asia Fresh News

Asia Fresh Stories

Archive for June 13th, 2014

OANDA Names New Chief Marketing Officer

leave a comment »

SINGAPOREJune 11, 2014 /PRNewswire/ — OANDA, a global provider of innovative forex trading services, is pleased to announce the appointment of Drew Izzo as Chief Marketing Officer (CMO). He will lead the award-winning broker’s global communications and marketing strategies.

An entrepreneurial, collaborative, and dynamic business leader with marketing and forex industry experience, Izzo most recently served as Chief Executive Officer of Athlete.com, a company he cofounded.

“With the perfect mix of entrepreneurial spirit, marketing vision, and forex experience, Drew is a valuable addition to our senior management team,” said Ed Eger, President and CEO, OANDA Corporation. “Coupling his bent for research and analytics as the backbone of a sound strategy, and with an emphasis on the customer’s voice, I know that Drew is a good for fit for the OANDA brand. He will further distinguish our company as an industry leader and the best choice for traders worldwide.”

Prior to cofounding Athlete.com, Izzo held several senior marketing roles for various companies including Interbank FX (IBFX), which was acquired by TradeStation in 2012. At IBFX, Izzo was responsible for all marketing channels across 140 countries.

“I’m excited to join OANDA, a world-class company that’s renowned for its transparency, technology, customer service and regulatory excellence,” Izzo said. “As CMO, I look forward to embracing the challenges and opportunities helping OANDA continue its remarkable success as the world’s leading forex broker.”

For more information, please visit www.oanda.sg, and follow OANDA on TwitterFacebook, or YouTube.

About OANDA

OANDA transformed the business of foreign exchange through an innovative approach to FX trading. The company’s industry leading online trading platform, fxTrade, introduced a number of firsts to the marketplace, including immediate execution; instant settlement on trades; trades of any size between one unit and 10 million units; and interest calculated by the second. The company’s many awards attest to the power and flexibility of its trading platform. In 2013, OANDA was honoured with nearly a dozen awards, including Best Trade Execution Provider, Best Retail Trading Platform and Best Mobile Trading Platform by International Finance Magazine; as well as Best Value for Money by Investment Trends in each of the U.S., UK, and Asia Pacific markets.

OANDA was also amongst the first online providers of comprehensive currency exchange information, and today the company’s OANDA Rate® data provides benchmark rates for corporations, auditing firms, and global banks.

OANDA has eight offices worldwide, in TorontoChicagoNew YorkBostonLondonSingaporeTokyo, andSydney. OANDA is fully regulated by the U.S. Commodity Futures Trading Commission (CFTC), the U.S. National Futures Association (NFA), the Monetary Authority of Singapore (MAS), the Investment Industry Regulatory Organization of Canada (IIROC), the UK Financial Conduct Authority (FCA), the Japanese Financial Services Agency (FSA), and the Australian Securities and Investments Commission (ASIC).

About OANDA Asia Pacific

This information is made available to you by OANDA Asia Pacific Pte Ltd. OANDA Asia Pacific Pte Ltd holds a Capital Markets Services Licence issued by the Monetary Authority of Singapore and is also licensed by the International Enterprise Singapore. Co Reg No. 200704926K. Trading in leveraged over-the-counter contracts for foreign currency, precious metals, and CFDs carries a high level of risk and may not be suitable for all investors. You should never put at risk any amount that you cannot afford to lose. More details under:http://www.oanda.sg/legal/risk-warning

© 1996 – 2014 OANDA Corporation. All rights reserved. All Registered Trade Marks used in this set of material, whether marked as Trade Marks or not marked, are declared to belong to their respective owner(s). OANDA Corporation owns Trade Marks of all its “FX” products.

The information on this material is not directed at residents of the United States, nor is it intended for distribution to, or use by, any person in any jurisdiction, where such distribution or use is contrary to local laws or regulations.

For more information, please contact:

Hoffman Agency for OANDA Asia Pacific
Jacintha Ng
Direct: +65-6361-0250
OANDASG@hoffman.com
www.hoffman.com

Source: OANDA Corporation

Written by asiafreshnews

June 13, 2014 at 6:45 pm

Posted in All releases

Weisman, Kennedy & Berris Co., L.P.A and Strauss Troy Co., LPA Announce Summary Notice of Pendency and Proposed Settlement of Shareholder Derivative Action

leave a comment »

CLEVELAND, June 12, 2014 /PRNewswire/ —

IN THE COURT OF COMMON PLEAS
CUYAHOGA COUNTY, OHIO

ALFRED STRAUS, Derivatively on Behalf of Nominal
Defendant Eaton Corporation, plc, and on Behalf of
Nominal Defendant Eaton Corporation,

Plaintiff,

Case No.: CV 11 748467

v.

Judge: John P. O’Donnell

MICHAEL J. CRITELLI, ALEXANDER M. CUTLER,
NET C. LAUTENBACH, DEBORAH L. McCOY,

GREGORY R. PAGE, CHARLES E. GOLDEN,
ARTHUR E. JOHNSON, TODD M. BLUEDORN,
GEORGE S. BARRETT, LINDA A HILL, GERALD B.
SMITH, VICTOR LEO, MARK MCGUIRE, TARAS
SZMAGALA, ERNIE GREENE, JOHN R. MILLER,
VICTOR A. PELSON, and GARY L. TOOKER,

SUMMARY NOTICE OF

Defendants,

PENDENCY AND

PROPOSED

and

SETTLEMENT OF

SHAREHOLDER

EATON CORPORATION, plc, and EATON
CORPORATION

DERIVATIVE ACTION

Nominal Defendants.

TO: ALL FORMER AND CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF EATON CORPORATION (“COMPANY”) OR EATON CORPORATION PLC (“PLC”) AS OF JUNE 6, 2014 (“STOCKHOLDERS”).

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the Cuyahoga County, Ohio Court of Common Pleas that a proposed settlement has been reached in this putative shareholder derivative action.

A hearing will be held on July 23, 2014, at 1:30 p.m., before the Honorable John P. O’Donnell in Courtroom 18-D at the Cuyahoga County Court of Common Pleas, 1200 Ontario Street, Cleveland, Ohio 44113‑1678, for the purpose of considering, among other things: (i) whether the proposed settlement will be approved by the Court pursuant to the terms of the Stipulation and Agreement of Settlement (“Stipulation”); (ii) whether the Court should enter a judgment dismissing Plaintiff’s Complaint with prejudice and on the merits, including and all claims which arise out of or are related to the facts and/or circumstances set forth in Complaint; and (iii) whether the Court should approve the award to be made to Plaintiff’s Counsel for Plaintiff’s attorney fees, expenses, costs, and an incentive payment to Plaintiff, up to a total of six million dollars ($6,000,000). The Court has reserved the right to reschedule the hearing without further notice.

Your rights as a Stockholder may be affected by this action and the proposed settlement. Additional details regarding this action, including the Notice of Pendency and Proposed Settlement of Shareholder Derivative Action (“Notice”), are available at http://www.weismanlaw.com. You may also contact a representative of Plaintiff’s Counsel, Weisman, Kennedy & Berris Co., L.P.A., 1600 Midland Building, 101 Prospect Avenue, W., Cleveland, Ohio 44115, telephone 800-475-1189 or 216-781-1111, or Strauss Troy Co., LPA, 150 East Fourth Street, Cincinnati, Ohio 45202-4018, telephone 513‑621-2120, for further information.

If you are a current Stockholder, you may have the right to object to any aspect of the Settlement and may appear in person or through counsel at the hearing. Stockholders who have no objection to the proposed settlement need not take any further action. Any objections to the settlement, including Plaintiff’s Counsel’s request for attorney fees, expenses, costs, and an incentive payment to Plaintiff, must be filed and served, in accordance with the procedures set forth in the Notice, no later than July 14, 2014.

IF YOU CHOOSE TO OBJECT, YOU MUST FOLLOW THE PROCEDURES SET FORTH IN THE NOTICE OR YOU WILL NOT BE HEARD, AND NO PAPERS, BRIEFS, OR OTHER DOCUMENTS BY YOU WILL BE RECEIVED AND CONSIDERED BY THE COURT.

Any Person who fails to object or otherwise request to be heard in the manner prescribed in the Notice will be deemed to have waived the right to object to any aspect of the settlement (including the right to appeal) or to request to be heard at the hearing, and will be forever barred from raising such objection or request in this or any other related action or proceeding.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK’S OFFICE ABOUT THIS NOTICE.

Dated: June 6, 2014

BY ORDER OF THE CUYAHOGA
COUNTY, OHIO COURT OF COMMON
PLEAS

Source: Weisman, Kennedy & Berris Co., L.P.A and Strauss Troy Co., LPA

Written by asiafreshnews

June 13, 2014 at 6:20 pm

Posted in Uncategorized

Enhanced ESET Mobile Security Now Available in APAC

leave a comment »

ESET launches new and improved mobile protection for Android at Mobile Asia Expo

SHANGHAI, June 11, 2014 /PRNewswire/ — ESET®, the global leader in proactive digital protection with a record of 10 consecutive years winning the prestigious VB100 awards with the company’s flagship ESET NOD32® security products, has announced the availability of the enhanced ESET Mobile Security in Asia Pacific.

The award winning ESET Mobile Security has been updated to include proactive Anti-Theft features, which helps Android users track lost or stolen mobile devices through an easy-to-use web interface at http://my.eset.com. While the basic protection is free for a lifetime, it’s up to users to decide if they want to subscribe and benefit from Premium features.

Proactive Anti-Theft detects potentially dangerous situations and takes preventative steps to ease the localization of stolen or lost device. The new functionality for Premium users sends the last location of the device when the battery hits critical level, takes snapshots from front and back camera when the wrong PIN/pattern is entered or an unauthorized SIM change is detected. All data on the device is accessible via the my.eset.com web interface.

ESET Mobile Security provides set of strong security features improving the Android experience without worrying about cyber threats and comes in free and premium versions. The free version of the application provides basic protection including full device scan, scan of downloaded applications items and basic Anti-Theft functionalities. All Premium features are unlocked after activating the 30-day trial or buying the license. In the premium version users will find Scheduled scanning, On-Charger scan, advanced Proactive Anti-Theft functionalities, including my.eset.com integration, SMS&Call filter and Security Audit.

Also introduced recently is an updated version of ESET Secure Authentication in Asia Pacific. Initially available only in selected regions, ESET’s updated two-factor authentication (2FA) application provides the potent combination of ultra-secure access to online applications, while introducing even greater ease of installation and support, for a super overall user experience. The added integration flexibility provided by the Software Development Kit (SDK) and API extends protection to a wider range of applications and data, making ESET Secure Authentication one of the most unique and compelling 2FA solutions on the market.

“The adoption of smartphones and tablets is growing at a rapid rate in Asia Pacific, with Android being the most popular OS with 59% market share. We rely on mobile devices in both our personal and professional lives to communicate, store data and even make financial transactions. Losing your device or experiencing a security breach is stressful and can put a lot of sensitive data at-risk,” said Parvinder Walia, Sales Director at ESET Asia Pacific. “Over the past year, we have received valuable feedback from our users on the importance of quick, efficient and easy device location and tracking and 2FA for added security. We’re proud to launch our new and improved versions of ESET Mobile Security and ESET Secure Authentication with features to better protect your mobile and online experience.”

To download a FREE version of ESET Mobile Security, please visit: https://play.google.com/store/apps/details?id=com.eset.ems2.gp

www.eset.com

Anna Goulding
Account Director
anna.goulding@ricecomms.com
Phone: +65-3157-5672
Mobile: +65-9112-4122

Source: ESET

Written by asiafreshnews

June 13, 2014 at 5:13 pm

Posted in All releases

Over 30 Taiwanese Jewellery Designers preparing to shine in the 2014 Taiwan Jewellery & Gem fair – Part I

leave a comment »

 

TAIPEI, June 12, 2014 /PRNewswire/ — Taiwan Jewellery & Gem Fair, the largest international jewellery fair in Taiwan will be held from November 21 to 24, 2014 at the Taipei World Trade Centre, Hall 1. Exhibitors from over 20 countries and regions, together with the local designers and industry leaders such as Chii Lih Coral and Chia Ta Jewellery have secured their spots to showcase their very best at this stellar event.

“First Love”, Maggie Wu, 18K gold, Icy Jadeite, Diamond
“First Love”, Maggie Wu,
18K gold, Icy Jadeite, Diamond
Charming, Tsai An Ho, The flower “violet” represents eternal beauty. The combination of titanium’s unique blue and violet with brilliant colour of tanzanite expresses brilliance
Charming, Tsai An Ho, The flower “violet” represents eternal beauty. The combination of titanium’s unique blue and violet with brilliant colour of tanzanite expresses brilliance
Flying Butterfly, Ammie Kang, An articulated brooch modelled to be a butterfly lying on a leave. The wings are set with 2 icy jadeite carvings decorated by diamonds and tsavorites together weighing approximately 7.03 and 5.49 carats respectively, mounted in 46.13g of 18 karat white gold, signed Kang.
Flying Butterfly, Ammie Kang, An articulated brooch modelled to be a butterfly lying on a leave. The wings are set with 2 icy jadeite carvings decorated by diamonds and tsavorites together weighing approximately 7.03 and 5.49 carats respectively, mounted in 46.13g of 18 karat white gold, signed Kang.

Taiwan jewellery designers demonstrating their innovative skills

Over 30 well-known local designers will gather at Taiwan Jewellery & Gem Fair to display their uniquely crafted designer pieces.  The designers’ area are grouped by “Taiwan Creative Jewellery Designer Association (TCJDA)” led by Ms. Wang, Yueh-Yaw and “Taiwan Jewellery Designer Association (TJDA)” led by Ms. Wu, Maggie.  In addition to the designers’ area, many well-known designers will be showcasing their own line, including Ms. Kang, Ammie and Ms. Tseng, Yuwen to name a couple.

Sneak Preview of Local Taiwanese Designers

Designer Ms. Wu, Maggie

Ms. Wu, Maggie is currently the Chairman of Taiwan Jewellery Designer Association and Council of Taipei Jewellery Workshop Union.  Ms. Wu’s design focuses preliminarily on jades for their soulful and solemn beauty, and restrained and understated elegance.  She incorporates her optimistic views in life as she cross paths with people of different origins and encounters situations into her designs, creating dazzling brilliance and beauty in each of her masterpiece.  Each stroke and line in the design marks her blessing of life.

Ms. Wu’s designer piece will be showcased in the designers’ area grouped with TJDA.

Designer Tsai, An Ho

Visual simulation on the natural beauty of nature is emphasized in Designer Tsai’s pieces.  His design is mainly inspired from the ever-changing nature, and the craftsmanship of each masterpiece is intricately crafted with much details.  In his designs, Mr. Tsai intertwines different colours, metals and materials into luxurious pieces.  Namely the plants and insects inspired pieces became his motif, his distinctive feature in his artistry, with which he has gained acclamation from collectors and auction houses worldwide.

Mr. Tsai’s designer piece will be showcased in the designers’ area grouped with TJDA.

Designer Kang, Ammie

Kang founded Top Kang Lapidary & Jewellery Arts in 1991 and began her own line of jewellery, specializing in jadeite jewelleries.  In 2007, her works were sold to private collectors at the Sotheby’s and the Christies auction.  Kang insists on using top grade gem stones and skilled craftsmen to attain her high demand for quality.  Her works seek to balance between tradition and fashion, combining the spirit of oriental tradition with the element of western fashion.  Each piece unique to itself, tells a story of its own.  Kang currently resides in Taichung, Taiwan and Toronto, Canada.

Ms. Kang will present her own line, Top Kang Lapidary & Jewellery Arts, at the Fair.

On-Site Events

In search for more talents, the Fair has partnered with the 2014 International Jewellery Design Competition to host a floral and butterfly themed design competition, display the winning designs and hold an award ceremony onsite.  Jewellery designers across the globe are encouraged to participate in the competition.  The competition is divided into two categories: (1) hand drawn and (2) computerized 3D graphics.  Participants will incorporate the vivid flowers and beautiful butterflies as the main elements into their designs, and the winning design will be used in the 2015 Jewellery Metal Smith Competition, where the inspiration will be turned into actual jewellery pieces before a crowd of audience onsite.

For more details on the exhibition, please contact:

UBM Asia Ltd., Taiwan Branch
Room 306, 3F, No. 51, KeeLung Road, Section 2, Taipei 11052, Taiwan
Tel:   +886-2-2738-3898
Fax: +886-2-2738-4886
Email: info-tw@ubm.com
Contact: Ms. Rita Hung

Show Website:
http://www.taiwanjewelleryfair.com

Facebook:
http://www.facebook.com/taiwanjewelry

Written by asiafreshnews

June 13, 2014 at 4:35 pm

Posted in Uncategorized

Philbeauty, the First Beauty Trade Show to Take Place Next Week in Manila

leave a comment »

 

MANILA, June 12, 2014 /PRNewswire/ — With less than a week to go the first beauty trade show has attracted strong interest from the beauty industry in the Philippines. Philbeauty 2014 will take place at the SMX Convention Centre in Manila, Philippines from 18th-20th June 2014.

Over 100 exhibiting companies from 22 countries and regions will be bringing together an exciting range of beauty products and services from all over the world. “We feel that it’s the right time for our products. The high economic growth in the Philippines will bring more attention on quality brands,” said Koji Miyno, Mitsukoshi Mesena Co. Ltd, Japan. Malaysian skincare and beauty manufacturer, Legacy Secret Marketing, wish to expand their network during the show: “Philbeauty gives me the opportunity to tap into the potential of the Philippine market as well as giving my brand regional exposure and recognition.”

Organised by UBM, philbeauty 2014 is the first B2B show in the Philippines for the beauty industry. Visitors to the show will also be able to enhance their industry knowledge and better anticipate market trends through the philbeauty International Beauty Conference. Pre-registered visitors enjoy free admission to the three day show as well as to the conference programme. Participants are able to listen to experts about topics ranging from the future of the ASEAN beauty industry to the latest innovations in the market as well as the process for registering products. In addition, live hair and make-up demonstrations will also be taking place on stage led by renowned celebrity stylist Mader Ricky Reyes.

M. Gandhi, Managing Director UBM ASEAN, said: “The strong response received from 22 exhibiting countries and regions shows that the Philippines is emerging as one of the most important markets in the global beauty industry. We have an excellent track record as a leading exhibition organiser, creating real business for exhibitors and buyers and philbeauty 2014 will create an essential industry gathering for beauty professionals.”

Philbeauty takes place from 18th-20th June 2014 at the SMX Convention Centre in Manila, Philippines. The event is free to attend for beauty professionals who register online at http://www.philbeautyshow.com

Written by asiafreshnews

June 13, 2014 at 4:27 pm

Posted in Uncategorized

HCL Research Reveals $39 Billion of SAP Landscape Could Move to the Cloud in the Next Two Years

leave a comment »

SINGAPORE /PRNewswire/ —

Global survey reveals integration and security as biggest inhibitors towards speedier SAP cloud migration

Research released today by HCL Technologies has revealed that $39 billion of SAP landscape could move to the cloud in the next two years, as large enterprises plan to migrate 46% of their existing SAP on-premise environment. The global survey of 100 executives from large enterprises focused on their current and future plans to deploy SAP applications and infrastructure in the cloud. It revealed that 45% of organizations have increased their SAP cloud investments over the past year and that they expect to nearly double these investments in the next 12 months. Migration isn’t just being motivated by potential cost savings, as the research highlights business agility and speed (59%), access to new technologies (46%) and improved customer satisfaction (43%) as big drivers.

“These findings clearly demonstrate that there is a market shift towards moving a greater proportion of existing SAP environments to the cloud,” said Steve Cardell, President of Enterprise Services and Diversified Industries, HCL Technologies. “Improved business agility and speed is undoubtedly a big driver, as is the growing maturity and availability of new cloud-based technologies. For those organizations looking to refresh their existing estates, reduce cost and access HANA-powered applications SAP’s cloud offerings are an attractive proposition. In fact, 56% of organizations stated they expect to use SAP HANA Enterprise Cloud in the future.”

When asked about the biggest inhibitors to moving more SAP applications and infrastructure to the cloud 30% of respondents noted integration challenges with existing systems, while 36% cited security concerns. This isn’t surprising considering 88% of organizations expected to adopt a hybrid model, while 45% stated that integration into their existing landscape had been their biggest cloud implementation challenge to date.

 

Written by asiafreshnews

June 13, 2014 at 3:56 pm

Posted in Uncategorized

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

leave a comment »

CORK, Ireland, June 12, 2014 /PRNewswire/ —

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen’s Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV’s Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

If successfully developed and approved by regulatory authorities, this treatment could offer people living with HIV who are virologically suppressed an option to switch from a standard three-drug therapy to a two-drug, Nucleoside Reverse Transcriptase Inhibitor (NRTI)-sparing antiviral regimen.

“HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients,” says Paul Stoffels, Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen. “We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens.”

Formulation and clinical development for the single tablet regimen will begin in the coming months.

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[1] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[1],[2],[3]

Standard HIV-drug therapy contains three active components: a backbone of two NRTIs, plus either a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Protease Inhibitor (PI) or Integrase Inhibitor (INI).

About EDURANT®

EDURANT® (rilpivirine) is a prescription HIV medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1)in adults:

  • Who have never taken HIV medicines before, and
  • Who have an amount of HIV in their blood (called “viral load”) that is no more than 100,000 copies/mL. Your healthcare professional will measure your viral load
  • EDURANT® should be taken in combination with other HIV medicines. Your healthcare professional will work with you to find the right combination of HIV medicines
  • It is important that you remain under the care of your healthcare professional during treatment with EDURANT®
  • EDURANT® is not recommended for patients less than 18 years of age

EDURANT® does not cure HIV infection or AIDS. You should remain on your HIV medications without stopping to ensure that you control your HIV infection and decrease the risk of HIV-related illnesses. Ask your healthcare professional about how to prevent passing HIV to other people.

Please read Important Safety Information below, and talk to your healthcare professional to learn if EDURANT® is right for you.

Important Safety Information

Can EDURANT® be taken with other medicines?

EDURANT® may affect the way other medicines work and other medicines may affect how EDURANT® works and may cause serious side effects. If you take certain medicines with EDURANT®, the amount of EDURANT® in your body may be too low and it may not work to help control your HIV infection, and the HIV virus in your body may become resistant to EDURANT® or other HIV medicines that are like it. To help get the right amount of medicine in your body, you should always take EDURANT® with a meal. A protein drink alone does not replace a meal.

Do not take EDURANT® if:

Your HIV infection has been previously treated with HIV medicines

You are taking any of the following medicines:

  • Anti-seizure medicines: carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol-XR®, Teril®, Epitol®), oxcarbazepine (Trileptal®), phenobarbital (Luminal®), phenytoin (Dilantin®, Dilantin-125®, Phenytek®)
  • Anti-tuberculosis (anti-TB) medicines: rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®), rifapentine (Priftin®)
  • Proton pump inhibitor (PPI) medicine for certain stomach or intestinal problems: esomeprazole (Nexium®, Vimovo®), lansoprazole (Prevacid®), omeprazole (Prilosec®, Zegerid®), pantoprazole sodium (Protonix®), rabeprazole (Aciphex®)
  • More than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate
  • St. John’s wort (Hypericum perforatum)

Especially tell your doctor if you take:

  • Rifabutin (Mycobutin®, a medicine to treat some bacterial infections). Talk to your doctor or pharmacist about the right amount of EDURANT® you should take if you also take rifabutin.
  • Medicines used to treat HIV
  • An antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. Take antacids at least 2 hours before or at least 4 hours after you take EDURANT®
  • Medicines to block acid in your stomach, including cimetidine (Tagamet®), famotidine (Pepcid®), nizatidine (Axid®), or ranitidine hydrochloride (Zantac®). Take these medicines at least 12 hours before or at least 4 hours after you take EDURANT®
  • Any of these medicines (if taken by mouth or injection): clarithromycin (Biaxin®), erythromycin (E-Mycin®, Eryc®, Ery-Tab®, PCE®, Pediazole®, Ilosone®), fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole (Nizoral®), methadone (Dolophine®), posaconazole (Noxafil®), telithromycin (Ketek®),voriconazole (Vfend®)

This is not a complete list of medicines. Before starting EDURANT®,
be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Before taking EDURANT®, also tell your healthcare professional if you have had or currently have liver problems (including hepatitis B or C), have ever had a mental health problem, are pregnant or planning to become pregnant, or breastfeeding. It is not known if EDURANT® will harm your unborn baby.

You and your healthcare professional will need to decide if taking EDURANT®is right for you.

  • Do not breastfeed if you are taking EDURANT®. You should not breastfeed if you have HIV because of the chance of passing HIV to your baby

What are the possible side effects of EDURANT®?

EDURANT® can cause serious side effects including:

  • Depression or mood changes. Tell your doctor right away if you have any of the following symptoms: feeling sad or hopeless, feeling anxious or restless, have thoughts of hurting yourself (suicide), or have tried to hurt yourself
  • Liver problems. People with a history of hepatitis B or C virus infection or who have certain liver function test changes may have an increased risk of developing new or worsening liver problems during treatment. Liver problems were also reported during treatment in some people without a history of liver disease. Your healthcare professional may need to do tests to check liver function before and during treatment
  • Changes in body shape or body fat have been seen in some patients taking HIV medicines. The exact cause and long-term health effects of these conditions are not known
  • Changes in your immune system (immune reconstitution syndrome).

Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection.

Other common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.

This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare professional right away. Do not stop taking EDURANT® or any other medications without first talking to your healthcare professional.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Product Information for more details:
http://www.edurant.com/sites/default/files/EDURANT-PI.pdf

About EDURANT® (rilpivirine)

Rilpivirine was developed by Janssen R&D Ireland Ltd, one of the Janssen Pharmaceutical Companies.

The registered formulation of rilpivirine is a 25 mg film-coated tablet taken orally once daily. Marketed as EDURANT®, rilpivirine is indicated, in combination with other ARVs, for the treatment of HIV-1 in ARV treatment-naïve adult patients. In most countries, including US and EU, this indication is further restricted to patients with a viral load < 100,000 copies/ mL.

Rilpivirine is available in the United States (US) and the European Union as part of a once daily fixed dose antiretroviral combination with Gilead Sciences Inc’s tenofovir and emtricitabine. This combination, known as COMPLERA® (US) or EVIPLERA®, was granted marketing authorisation from the Food and Drug Administration in August 2011, with Gilead Sciences Inc being the marketing authorisation holder in the US, and from the European Commission in November 2011, with Gilead Sciences International Ltd. being the marketing authorisation holder in Europe, Middle East and Africa.

About TIVICAY® (dolutegravir)

TIVICAY® (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. It is available as a small, yellow, 50 mg tablet. Importantly, it can be taken with or without food and at any time of the day.

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

(This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland Ltd, any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson.

Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; general industry conditions including trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.

A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.)

1. World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/gho/hiv/en/. Last accessed June 2014.

2. Hui Dy. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; http://www.ncbi.nlm.nih.gov/pubmed/12547652 42(2):81-92.

3. World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/hiv/data/2012_epi_core_en.png. Last accessed June 2014.

MEDIA CONTACT:
Ronan Collins
+47-488-42500
rcollin5@its.jnj.com

INVESTOR RELATIONS:
Stan Panasewicz
+1-732-524-2524

Louise Mehrotra
+1-732-524-6491

Written by asiafreshnews

June 13, 2014 at 3:27 pm

Posted in Uncategorized

Herman Miller Brings Living Office(SM) to Life

leave a comment »

ZEELAND, Michigan/PRNewswire/ — In 2013 Herman Miller introduced Living Office, an enlightened and more human-centered framework to approach contemporary office design. Continuing the company’s legacy of leadership in the design of the modern workplace, Living Office addresses wants and needs that are fundamental to all humans, while adaptive to the unique purpose, character and activities of individuals and organizations. Ultimately, Herman Miller’s Living Office seeks to inspire and enable a more natural and desirable workplace, fostering greater connection, creativity, productivity, and prosperity for all.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/7242951-herman-miller-brings-living-office-life-new-insights-tools-furnishings

Photo – http://photos.prnewswire.com/prnh/20140611/116856

Building on the momentum of its Living Office launch, this week Herman Miller unveiled new tools, information, and dynamic new furniture designs to help organizations achieve their own Living Office.

The Power of Place
In a Living Office, place acts as a powerful expression of an organization’s unique culture and a strategic tool to realize its ambitions. The guiding design principles start with those factors that are fundamental to all humans; and because all individuals and companies work differently, diagnostic tools then focus on those qualities that are unique to each.

A Human Experience Fundamental to All
Living Office begins with an understanding of what all people intuitively seek in a workplace. To create offices where people and the business can prosper, Herman Miller believes organizations must develop spaces that balance the experiences and motivations of individuals and groups, as well as their cognitive and physical needs. The Living Office tools for modeling the human experience also account for the natural interaction of these dimensions.

Human Motivation
Herman Miller has identified six key work motivations, informed by independent experts and the company’s own primary research, and considers each in relation to the individual, group, cognitive, and physical experience.

  • Security: People desire health, safety, familiarity, and competence.
  • Autonomy: We naturally seek freedom in our actions and decisions.
  • Belonging: Humans want meaningful connection to others.
  • Achievement: We strive for excellence and take pride in our accomplishments.
  • Status: We want recognition for our contributions.
  • Purpose: People want to make a meaningful difference.

Greg ParsonsHerman Miller’s Vice President, New Landscape of Work, noted, “Today’s technologies allow us to work anywhere. So why come to an office at all? Living Office aims to provide to knowledge workers what the stage or recording studio offers to musicians- an environment optimized to inspire and enable people’s ultimate performance. By deeply understanding human motivations and their corollaries in space design, Living Office enhances both performance and satisfaction.”

The company has research-based examples of how these six motivators connect to the design of the office. InHerman Miller’s global study on individual preferences and attributes, people who said they were motivated by connection and belonging cited preferences for a “personal oasis” at work that supports “self-identity and ownership.” They also expressed desire for work environments that “do not look or feel like an office, but seem more like home,” that “flow between casual and formal,” “reflect team space,” and “enable and encourage interactions.”

In the same global study, people who said they were motivated by meaningful and engaging work cited preferences for “busy, interactive” work environments that offered “freedom to explore” and “different perspectives and viewpoints.” Providing people the option to select work settings that best serve the task at hand supports their desire for autonomy.

Purpose and Character
Each Living Office relies on an understanding of business purpose and priorities. Herman Miller defines purpose as what an organization offers the world and what it hopes to receive in return. Business priorities are those things that either impede or aid the achievement of purpose — such as attracting talent and stimulating innovation.

Character is that distinct set of values and traits that best define a person or business in comparison to others. Living Office utilizes a spectrum of character attributes in eight distinct dualities to facilitate a conversation about an organization’s essential nature. They include: Constant to Adaptable, Uniform to Diverse, Formal to Casual, Closed to Open, Physical to Virtual, Local to Global, Independent to Interdependent, and Directed to Self-Directed.

Herman Miller believes that a workplace that expresses character helps people align with common goals and aspirations, while offering a variety of spaces with their own distinct character contributes a feeling of vitality and guides utility.

Activities
Because organizations, teams, and individuals all work differently, Herman Miller believes understanding and accommodating the unique activities that comprise work is critical to the design of each Living Office. Its Modes of Work research and associated Settings define and support the entire spectrum of needs as people move through their workday.

Knowledge and Tools
Working with many of the world’s leading researchers, subject experts and designers, Herman Miller is introducing this new knowledge with related services, products, and technologies to support its progressive vision.

Locale
Designed by UK-based Sam Hecht and Kim Colin, Locale helps organizations better utilize and manage open offices with a system that enables seamless transitions between work done together and alone, and in seated or standing postures. By removing visual and physical obstacles and condensing the architectural scale of an open plan office into a tightly knit neighborhood, Locale helps people stay better connected to their work and each other. During the design process for Locale, Hecht and Colin drew on their own office for inspiration — a highly efficient space that accommodates different work styles and behaves like an energetic international neighborhood. The design drew upon the notion of a thriving English high street, which serves the community and broader city simply and effectively, by arranging a variety of local activities and services in close proximity.

Public Office Landscape
Public transforms every part of the office — including the individual desk — into places for greater collaboration. Designed by Yves Behar and fuseproject, it’s the first office system to support casual work and provide comfort, at the desk, in circulation space, and in group areas — all within a consistent design vocabulary. Visually uniform and modular surfaces, storage, and seating can be configured into a broad range of settings that encourage fluid transitions between collaborative and focused work. The Social Chair is the core component of the Public system, bringing new ergonomics, functionality and durability to soft seating while accommodating a range of people and postures. Public is a new landscape platform that encourages the purposeful interactions that drive work forward — at the desk, in group areas, and throughout the entire office.

Living Office for All
Living Office offers individuals and organizations a strategy to respond to the new landscape of work. By putting people and their passion first, it is a way to rethink why, how, and where work happens, while recognizing our humanity is an asset, not a liability. For that reason, Herman Miller declares a Living Office isn’t for everyone — but for each of us, with greater prosperity for all.

About Herman Miller
Herman Miller’s inspiring designs, inventive technologies and strategic services help people do great things and organizations to perform at their best. The company’s award-winning products and services generated approximately $1.8 billion in revenue in fiscal 2013. A past recipient of the Smithsonian Institution’s Cooper-Hewitt National Design Award, Herman Miller designs can be found in the permanent collections of museums worldwide. Innovative business practices and a commitment to social responsibility have also helped establishHerman Miller as a recognized global leader. Herman Miller is included in the Dow Jones Sustainability World Index and trades on the NASDAQ Global Select Market under the symbol MLHR.

Source: Herman Miller, Inc.

Written by asiafreshnews

June 13, 2014 at 11:16 am

Posted in Uncategorized